OTC:CC - Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned
(TheNewswire)
Calgary, Alberta – TheNewswire - December 7, 2023 - Ocumetics Technology Corp.(“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO),a pioneer in the field of ophthalmic innovation,proudly confirms the successful completion of its biocompatibilityanimal study, in preparation for its first-in-human study, anticipatedto commence in Q1 2024 in the Dominican Republic.
The biocompatibility of the Ocumetics accommodatingintraocular lens (the “ Ocumetics Accommodating Lens” ) was evaluatedby surgical implantation of two lenses into the eyes of rabbits. Thefirst lens, the Ocumetics Accommodating Lens, was compared to thesecond lens, a commercially available monofocal intraocular lens(“ IOL ”) as a control. Results from this three-month animal studydemonstrated that there were no biocompatibility or safety issuesrelated to the Ocumetics Accommodating Lens when compared to thecontrol IOL.
The study also evaluated the occurrence of anterior andposterior capsular opacification in the rabbit model over the threemonth period. There were no significant differences between the twoIOL groups in terms of posterior capsular opacification and anteriorcapsular opacification at the end of the study.
Dr. Garth Webb, Founder and Chief Scientific Officer ofOcumetics, expressed enthusiasm about the outcomes, emphasizing,"Our primary focus in this study was to assess the surgicalimplantation performance of our revolutionary accommodatingintraocular lens design. I am thrilled to report that the resultsnot only met, but surpassed our expectations. This marks therealization of years of dedicated technological advancement."
Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, shed light onthe Ocumetics Accommodating Lens innovation, stating, "Our latestlens design caters to the needs of ophthalmologists by offeringprecise control during implantation, ensuring a gradual unfoldingwithin the capsular bag. This new lens design was enthusiasticallyreceived by our Medical Advisory Board and should assure broadacceptance by ophthalmic surgeons immediately after US FDA marketingapproval.”
Dean Burns, President & CEO of Ocumetics, sharedthe roadmap ahead, "This successful study is a major milestonefor Ocumetics, and a critical step for us to continue our journeytowards US FDA approval. We anticipate initiating our first-in-humanproof of concept studies in Q1 2024. These latest results are atestament to our team’s skill and dedication, and we eagerlyanticipate the launch of human trials."
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO),headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated todeveloping and commercializing advanced vision correction solutionsthat enhance the quality of life for individuals worldwide.
Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. In its pursuitof a next generation interocular lens solution, Ocumetics hasdeveloped the Ocumetics Accommodating Lens, an expandable intraocularlens that fits within the natural lens compartment of the eyepotentially to eliminate the need for corrective lenses. It isdesigned to allow the eye’s natural muscle activity to seamlesslyshift focus from distance to intermediate to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns Dayton Marks
President and CEO Director
(817) 874-7564 (778)347-2500
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.